

Cristian Turato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/998481/publications.pdf>

Version: 2024-02-01

86
papers

985
citations

430442

18
h-index

476904

29
g-index

87
all docs

87
docs citations

87
times ranked

1214
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | SERPINB3 induces epithelial→mesenchymal transition. <i>Journal of Pathology</i> , 2010, 221, 343-356. | 2.1 | 77 |
| 2 | High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection. <i>Thorax</i> , 2020, 75, 998-1000. | 2.7 | 76 |
| 3 | Hypoxia up-regulates SERPINB3 through HIF-2 β in human liver cancer cells. <i>Oncotarget</i> , 2015, 6, 2206-2221. | 0.8 | 59 |
| 4 | SERPINB3 is associated with TGF- β 1 and cytoplasmic β -catenin expression in hepatocellular carcinomas with poor prognosis. <i>British Journal of Cancer</i> , 2014, 110, 2708-2715. | 2.9 | 57 |
| 5 | SERPINB3 protects from oxidative damage by chemotherapeutics through inhibition of mitochondrial respiratory complex I. <i>Oncotarget</i> , 2014, 5, 2418-2427. | 0.8 | 57 |
| 6 | SERPINB3 modulates TGF- β 2 expression in chronic liver disease. <i>Laboratory Investigation</i> , 2010, 90, 1016-1023. | 1.7 | 43 |
| 7 | Over-expression of SERPINB3 in hepatoblastoma: A possible insight into the genesis of this tumour?. <i>European Journal of Cancer</i> , 2012, 48, 1219-1226. | 1.3 | 43 |
| 8 | MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 171. | 1.0 | 37 |
| 9 | New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma. <i>Journal of Controlled Release</i> , 2017, 268, 184-197. | 4.8 | 33 |
| 10 | SerpinB3 and Yap Interplay Increases Myc Oncogenic Activity. <i>Scientific Reports</i> , 2016, 5, 17701. | 1.6 | 31 |
| 11 | The molecular signature of impaired diabetic wound healing identifies serpinB3 as a healing biomarker. <i>Diabetologia</i> , 2014, 57, 1947-1956. | 2.9 | 28 |
| 12 | Binding and Uptake into Human Hepatocellular Carcinoma Cells of Peptide-Functionalized Gold Nanoparticles. <i>Bioconjugate Chemistry</i> , 2017, 28, 222-229. | 1.8 | 25 |
| 13 | Hepatic progenitor cells express SerpinB3. <i>BMC Cell Biology</i> , 2014, 15, 5. | 3.0 | 23 |
| 14 | SerpinB3 Promotes Pro-fibrogenic Responses in Activated Hepatic Stellate Cells. <i>Scientific Reports</i> , 2017, 7, 3420. | 1.6 | 23 |
| 15 | SerpinB3 Differently Up-Regulates Hypoxia Inducible Factors -1 β and -2 β in Hepatocellular Carcinoma: Mechanisms Revealing Novel Potential Therapeutic Targets. <i>Cancers</i> , 2019, 11, 1933. | 1.7 | 22 |
| 16 | IgM-Linked SerpinB3 and SerpinB4 in Sera of Patients with Chronic Liver Disease. <i>PLoS ONE</i> , 2012, 7, e40658. | 1.1 | 22 |
| 17 | Increased myoendothelial gap junctions mediate the enhanced response to epoxyeicosatrienoic acid and acetylcholine in mesenteric arterial vessels of cirrhotic rats. <i>Liver International</i> , 2011, 31, 881-890. | 1.9 | 21 |
| 18 | Squamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity. <i>Cancer Science</i> , 2019, 110, 1552-1563. | 1.7 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection. <i>Experimental Biology and Medicine</i> , 2012, 237, 793-802. | 1.1 | 20 |
| 20 | Role of squamous cell carcinoma antigen-1 on liver cells after partial hepatectomy in transgenic mice. <i>International Journal of Molecular Medicine</i> , 2010, 25, 137-43. | 1.8 | 19 |
| 21 | Inhibition of epoxyeicosatrienoic acid production in rats with cirrhosis has beneficial effects on portal hypertension by reducing splanchnic vasodilation. <i>Hepatology</i> , 2016, 64, 923-930. | 3.6 | 18 |
| 22 | High-flow nasal cannula oxygen therapy to treat acute respiratory failure in patients with acute exacerbation of idiopathic pulmonary fibrosis. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661984713. | 1.0 | 18 |
| 23 | Increased antiprotease activity of the SERPINB3 polymorphic variant SCCA-PD. <i>Experimental Biology and Medicine</i> , 2011, 236, 281-290. | 1.1 | 17 |
| 24 | PreS1 peptide-functionalized gold nanostructures with SERRS tags for efficient liver cancer cell targeting. <i>Materials Science and Engineering C</i> , 2019, 103, 109762. | 3.8 | 17 |
| 25 | Pirfenidone improves the survival of patients with idiopathic pulmonary fibrosis hospitalized for acute exacerbation. <i>Current Medical Research and Opinion</i> , 2019, 35, 1187-1190. | 0.9 | 16 |
| 26 | MicroRNAs and SerpinB3 in hepatocellular carcinoma. <i>Life Sciences</i> , 2014, 100, 9-17. | 2.0 | 15 |
| 27 | SERPINB3 (Serpin Peptidase Inhibitor, Clade B (Ovalbumin), Member 3). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2015, 19, 202-209. | 0.1 | 15 |
| 28 | Hyaluronated and PEGylated Liposomes as a Potential Drug-Delivery Strategy to Specifically Target Liver Cancer and Inflammatory Cells. <i>Molecules</i> , 2022, 27, 1062. | 1.7 | 14 |
| 29 | SERPINB3 is associated with longer survival in transgenic mice. <i>Scientific Reports</i> , 2013, 3, 3056. | 1.6 | 12 |
| 30 | Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis. <i>Journal of Pathology</i> , 2022, 257, 82-95. | 2.1 | 12 |
| 31 | Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease. <i>Digestive and Liver Disease</i> , 2009, 41, 212-216. | 0.4 | 10 |
| 32 | Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 422. | 1.0 | 10 |
| 33 | SerpinB3 as a Pro-Inflammatory Mediator in the Progression of Experimental Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 9 |
| 34 | SerpinB3 induces dipeptidyl-peptidase IV/CD26 expression and its metabolic effects in hepatocellular carcinoma. <i>Life Sciences</i> , 2018, 200, 134-141. | 2.0 | 8 |
| 35 | Spontaneous pneumomediastinum complicating severe acute asthma exacerbation in adult patients. <i>Journal of Asthma</i> , 2018, 55, 1028-1034. | 0.9 | 8 |
| 36 | Prone Positioning Is Safe and May Reduce the Rate of Intubation in Selected COVID-19 Patients Receiving High-Flow Nasal Oxygen Therapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 3404. | 1.0 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Increased Th1 immune response in SERPINB3 transgenic mice during acute liver failure. <i>Experimental Biology and Medicine</i> , 2012, 237, 1474-1482. | 1.1 | 7 |
| 38 | Low P66shc with High SerpinB3 Levels Favors Necroptosis and Better Survival in Hepatocellular Carcinoma. <i>Biology</i> , 2021, 10, 363. | 1.3 | 7 |
| 39 | Role of squamous cell carcinoma antigen-1 on liver cells after partial hepatectomy in transgenic mice. <i>International Journal of Molecular Medicine</i> , 2009, 25, . | 1.8 | 6 |
| 40 | Changes in gene expression of cytochrome P-450 in liver, kidney and aorta of cirrhotic rats. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 120, 134-138. | 1.0 | 4 |
| 41 | Effect of a passive exhalation port on tracheostomy ventilation in amyotrophic lateral sclerosis patients: a randomized controlled trial. <i>Journal of Thoracic Disease</i> , 2018, 10, 1007-1014. | 0.6 | 4 |
| 42 | Non-Invasive Ventilation for Acute Respiratory Failure in Duchenne Muscular Dystrophy Patients. <i>Archivos De Bronconeumologia</i> , 2021, 57, 666-668. | 0.4 | 3 |
| 43 | SERPINB3 induces epithelial mesenchymal transition. <i>Digestive and Liver Disease</i> , 2009, 41, A1-A2. | 0.4 | 2 |
| 44 | Serpinb3 is Overexpressed in the Liver in Presence of Iron Overload. <i>Journal of Investigative Medicine</i> , 2018, 66, 32-38. | 0.7 | 2 |
| 45 | 71 HYPOXIA UP-REGULATES SERPIN B3 IN HEPATIC CANCER CELLS: A HIF-2 $\hat{\pm}$ ASSOCIATED EVENT RELATED TO INVASIVENESS AND EPITHELIAL TO MESENCHYMAL TRANSITION. <i>Journal of Hepatology</i> , 2010, 52, S33. | 1.8 | 1 |
| 46 | OC-4 Over-expression of SERPINB3 in hepatoblastoma: A possible insight into the genesis of this tumor?. <i>Digestive and Liver Disease</i> , 2011, 43, S66. | 0.4 | 1 |
| 47 | SerpinB3 up-regulates hypoxia inducible factors-1 $\hat{\pm}$ and -2 $\hat{\pm}$ in liver cancer cells through different mechanisms. <i>Digestive and Liver Disease</i> , 2016, 48, e19. | 0.4 | 1 |
| 48 | Oncostatin M induces increased invasiveness and angiogenesis in hepatic cancer cells through HIF1 $\hat{\pm}$ -related release of VEGF-A. <i>Digestive and Liver Disease</i> , 2017, 49, e5. | 0.4 | 1 |
| 49 | Engineered EVs for Oxidative Stress Protection. <i>Pharmaceuticals</i> , 2021, 14, 703. | 1.7 | 1 |
| 50 | Liver pro-oncogenic potential of SERPINB3. <i>Oncoscience</i> , 2014, 1, 502-503. | 0.9 | 1 |
| 51 | Serpin B3 up-regulation by hypoxia in HepG2 cells: A redox sensitive, Ras/ERK and PI3-K mediated event related to invasiveness and epithelial to mesenchymal transition. <i>Digestive and Liver Disease</i> , 2009, 41, A19. | 0.4 | 0 |
| 52 | 856 HEPATIC PROGENITOR CELLS OVEREXPRESS SERPINB3 IN A MOUSE MODEL OF FULMINANT HEPATITIS. <i>Journal of Hepatology</i> , 2009, 50, S312. | 1.8 | 0 |
| 53 | F.N.23 HYPOXIA UP-REGULATES SERPIN B3 IN HEPATIC CANCER CELLS BY A HIF-2 $\hat{\pm}$ -DEPENDENT MECHANISM. <i>Digestive and Liver Disease</i> , 2010, 42, S41-S42. | 0.4 | 0 |
| 54 | T-5 Oncostatin M, overexpressed in hepatocellular carcinoma, up-regulates SERPIN-B3 expression in hepatic cancer cells. <i>Digestive and Liver Disease</i> , 2011, 43, S78. | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | 262 SERPINB3 IS ASSOCIATED TO LONGER SURVIVAL IN MALE TRANSGENIC MICE. <i>Journal of Hepatology</i> , 2011, 54, S108. | 1.8 | 0 |
| 56 | 1033 SERPIN-B3 INDUCES HIF2 α NUCLEAR TRANSLOCATION IN HEPATIC CANCER CELLS: A PARACRINE LOOP ABLE TO AFFECT CANCER CELL BEHAVIOUR. <i>Journal of Hepatology</i> , 2013, 58, S424-S425. | 1.8 | 0 |
| 57 | 1036 SERPINB3 INCREASES RESISTANCE TO CHEMOTHERAPEUTIC AGENTS INHIBITING ROS PRODUCTION AND THE PERMEABILITY TRANSITION PORE. <i>Journal of Hepatology</i> , 2013, 58, S425-S426. | 1.8 | 0 |
| 58 | 1129 SERPIN-B3 AS A PRO-FIBROGENIC MEDIATOR CONTRIBUTING TO CHRONIC LIVER DISEASE PROGRESSION. <i>Journal of Hepatology</i> , 2013, 58, S460. | 1.8 | 0 |
| 59 | P1260 IRON-DEPENDENT REGULATION OF SERPINB3. <i>Journal of Hepatology</i> , 2014, 60, S509. | 1.8 | 0 |
| 60 | P0270 : SerpinB3 and Yap interplay increases Myc oncogenic activity. <i>Journal of Hepatology</i> , 2015, 62, S407-S408. | 1.8 | 0 |
| 61 | HIF2 α neddylation as a selective SerpinB3-dependent mechanism leading to its increased stabilization and nuclear translocation in liver cancer cells. <i>Digestive and Liver Disease</i> , 2015, 47, e32. | 0.4 | 0 |
| 62 | Positive correlation of HIF2 α and SERPINB3 in human hepatocellular carcinoma: selectivity and prognostic implications. <i>Digestive and Liver Disease</i> , 2015, 47, e41-e42. | 0.4 | 0 |
| 63 | SerpinB3 and Yap interplay increases Myc oncogenic activity. <i>Digestive and Liver Disease</i> , 2015, 47, e31. | 0.4 | 0 |
| 64 | P0276 : HIF2-alpha neddylation as a selective SerpinB3-dependent mechanism leading to its increase. <i>Journal of Hepatology</i> , 2015, 62, S410. | 1.8 | 0 |
| 65 | Exogenous administration of recombinant SERPINB3 inhibits cell reprogramming. <i>Digestive and Liver Disease</i> , 2016, 48, e29. | 0.4 | 0 |
| 66 | P66shc and SerpinB3 interplay affects HCC clinical outcome and cell fate. <i>Digestive and Liver Disease</i> , 2016, 48, e30. | 0.4 | 0 |
| 67 | DPPIV/CD26 and SerpinB3 interaction affects metabolism and clinical outcome in hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, e49. | 0.4 | 0 |
| 68 | The Protease-Inhibitor SERPINB3 Activates Canonical WNT Pathway in Monocytes. <i>Journal of Hepatology</i> , 2016, 64, S556-S557. | 1.8 | 0 |
| 69 | Serpinb3 Up-Regulates Hypoxia Inducible Factors-1alpha and -2alpha in Liver Cancer Cells through Different Mechanisms. <i>Journal of Hepatology</i> , 2016, 64, S579-S580. | 1.8 | 0 |
| 70 | Exogenous Administration of SERPINB3 Inhibits Cell Reprogramming. <i>Journal of Hepatology</i> , 2016, 64, S563. | 1.8 | 0 |
| 71 | The protease-inhibitor SerpinB3 modulate survival and Wnt pathway of inflammatory human monocytes. <i>Digestive and Liver Disease</i> , 2016, 48, e27. | 0.4 | 0 |
| 72 | Role of SerpinB3 in the stimulation of macrophage activation marker sCD163 in HCV infected patients. <i>Digestive and Liver Disease</i> , 2017, 49, e6. | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | The immunomodulatory activity of SerpinB3 an protease-inhibitor in vivo and in vitro. Digestive and Liver Disease, 2017, 49, e26. | 0.4 | 0 |
| 74 | MiR-122 targets SerpinB3 and is involved in Sorafenib resistance in hepatocellular carcinoma. Digestive and Liver Disease, 2017, 49, e28. | 0.4 | 0 |
| 75 | Role of SerpinB3 in the stimulation of macrophage activation marker sCD163 in hepatitis C virus infected patients. Journal of Hepatology, 2017, 66, S325. | 1.8 | 0 |
| 76 | Oncostatin M induces increased invasiveness and angiogenesis in hepatic cancer cells through HIF1alpha-related release of VEGF-A. Journal of Hepatology, 2017, 66, S634. | 1.8 | 0 |
| 77 | The immunomodulatory activity of the protease-inhibitor SerpinB3 in vivo and in vitro. Journal of Hepatology, 2017, 66, S163-S164. | 1.8 | 0 |
| 78 | FRI-117-The gain of function mutation of SerpinB3 (SCCA-PD) is associated with the severity of portal hypertension and complications onset in patients with advanced liver disease. Journal of Hepatology, 2019, 70, e438-e439. | 1.8 | 0 |
| 79 | Hepatic ischemia induces a time-dependent increase in SerpinB3 gene expression. Digestive and Liver Disease, 2020, 52, e65-e66. | 0.4 | 0 |
| 80 | Hepatic ischemia induces a time-dependent increase in SERPINB3 gene expression. Journal of Hepatology, 2020, 73, S284. | 1.8 | 0 |
| 81 | SERPINB3 inhibition as a novel target therapy for non-alcoholic steatohepatitis. Journal of Hepatology, 2020, 73, S671. | 1.8 | 0 |
| 82 | SerpinB3 inhibition as a novel target therapy for non-alcoholic steatohepatitis. Digestive and Liver Disease, 2020, 52, e39-e40. | 0.4 | 0 |
| 83 | Non-Invasive Ventilation for Acute Respiratory Failure in Duchenne Muscular Dystrophy Patients. Archivos De Bronconeumologia, 2021, 57, 666-668. | 0.4 | 0 |
| 84 | HIF1 α mediates hypoxia-dependent upregulation of SerpinB3, a marker of early liver carcinogenesis (144.7). FASEB Journal, 2014, 28, 144.7. | 0.2 | 0 |
| 85 | Use of a passive exhalation port for long-term tracheostomy ventilation in patients with Amyotrophic Lateral Sclerosis: a randomized control trial. , 2017, , . | | 0 |
| 86 | Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis. Digestive and Liver Disease, 2022, 54, S41. | 0.4 | 0 |